Nautilus Biotechnology Q3 net loss narrows on lower operating expenses

Nautilus Biotechnology

28/10/2025 12:12

Overview

Nautilus Q3 operating expenses decreased 19% yr/yr due to operating efficiencies

Net loss for Q3 was $13.6 mln, down from $16.4 mln in prior year period

Company holds $168.5 mln in cash, cash equivalents, and investments as of Sept 30, 2025

Outlook

Nautilus plans to launch early access program for Tau proteoforms in H1 2026

Company targets full commercial launch of proteome platform in late 2026

Result Drivers

TAU PROTEOFORMS - Progress in processing Tau proteoform samples for product validation and publications, with data to be shared at World HUPO conference

NEW ASSAY DEVELOPMENT - Development of new broadscale assay format to support commercial launch in late 2026

OPERATING EFFICIENCIES - Decrease in operating expenses attributed to efficiencies, lower development costs, and decreased salaries and compensation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.11
Q3 Net Income
-$13.57 mln
Q3 Operating Expenses
$15.47 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $2.50, about 46% above its October 27 closing price of $1.35

Press Release: ID:nGNX2LXy3C

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)